TLR9 and TLR7 agonists mediate distinct type I IFN responses in humans and nonhuman primates in vitro and in vivo

Journal of Leukocyte Biology

Volumn 91, Issue 1, 2012, Pages 147-158

  Puig, Montserrat ^a   Tosh, Kevin W ^a   Schramm, Lynnsie M ^b   Grajkowska, Lucja T ^a   Kirschman, Kevin D ^b   Tami, Cecilia ^a   Beren, Joel ^c   Rabin, Ronald L ^b   Verthelyi, Daniela ^a  

^a Center for Drug Evaluation and Research   (United States)

^b Parasite and Allergenic Products   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

CpG ODN; Imiquimod; Interferon subtypes; Macaques; Skin

Indexed keywords

ALPHA1 INTERFERON; ALPHA10 INTERFERON; ALPHA14 INTERFERON; ALPHA16 INTERFERON; ALPHA2 INTERFERON; ALPHA21 INTERFERON; ALPHA7 INTERFERON; ALPHA8 INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; IMIQUIMOD; INTERFERON; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACACA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

AMINOQUINOLINES; ANIMALS; GENE EXPRESSION REGULATION; HUMANS; INTERFERON TYPE I; MACACA MULATTA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9;

MACACA; PRIMATES;

EID: 84855323411     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0711371     Document Type: Article

References (60)

1. Fitzgerald-Bocarsly, P., Dai, J., Singh, S. (2008) Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev. 19, 3-19.
2. Gregorio, J., Meller, S., Conrad, C., Di Nardo, A., Homey, B., Lauerma, A., Arai, N., Gallo, R. L., DiGiovanni, J., Gilliet, M. (2010) Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons. J. Exp. Med. 207, 2921-2930.
3. Gursel, M., Verthelyi, D., Klinman, D. M. (2002) CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells. Eur. J. Immunol. 32, 2617-2622.
4. Chang, J. J., Altfeld, M. (2010) Innate immune activation in primary HIV-1 infection. J. Infect. Dis. 202, S297-S301.
5. Guarda, G., Braun, M., Staehli, F., Tardivel, A., Mattmann, C., Förster, I., Farlik, M., Decker, T., Du Pasquier, R. A., Romero, P., Tschopp, J. (2011) Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34, 213-223.
6. Pestka, S. (2007) The interferons: 50 years after their discovery, there is much more to learn. J. Biol. Chem. 282, 20047-20051.
7. Chen, J., Baig, E., Fish, E. N. (2004) Diversity and relatedness among the type I interferons. J. Interferon Cytokine Res. 24, 687-698.
8. Antonelli, G. (2008) Biological basis for a proper clinical application of α interferons. New Microbiol. 31, 305-318.
9. Woelk, C. H., Frost, S. D. W., Richman, D. D., Higley, P. E., Kosakovsky Pond, S. L. (2007) Evolution of the interferon α gene family in eutherian mammals. Gene 397, 38-50.
10. Yamamoto, S., Yano, H., Sanou, O., Ikegami, H., Kurimoto, M., Kojiro, M. (2002) Different antiviral activities of IFN-α subtypes in human liver cell lines: synergism between IFN-α and IFN-α 8. Hepatol. Res. 24, 99-106.
11. Sperber, S. J., Hunger, S. B., Schwartz, B., Pestka, S. (1993) Anti-rhinoviral activity of recombinant and hybrid species of interferon α. Antiviral Res. 22, 121-129.
12. Sperber, S. J., Gocke, D. J., Haberzettl, C., Kuk, R., Schwartz, B., Pestka, S. (1992) Anti-HIV-1 activity of recombinant and hybrid species of interferon-α. J. Interferon Res. 12, 363-368.
13. Akira, S., Hemmi, H. (2003) Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett. 85, 85-95.
14. Khoo, J. J., Forster, S., Mansell, A. (2011) Toll-like receptors as interferon-regulated genes and their role in disease. J. Interferon Cytokine Res. 31, 13-25.
15. Klinman, D. M. (2004) Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4, 249-258.
16. Verthelyi, D., Zeuner, R. A. (2003) Differential signaling by CpG DNA in DCs and B cells: not just TLR9. Trends Immunol. 24, 519-522.
17. Hoshino, K., Sugiyama, T., Matsumoto, M., Tanaka, T., Saito, M., Hemmi, H., Ohara, O., Akira, S., Kaisho, T. (2006) IKB kinase-α is critical for interferon-α production induced by Toll-like receptors 7 and 9. Nature 440, 949-953.
18. Barbalat, R., Ewald, S. E., Mouchess, M. L., Barton, G. M. (2011) Nucleic acid recognition by the innate immune system. Annu. Rev. Immunol. 29, 185-214.
19. Verthelyi, D., Ishii, K. J., Gursel, M., Takeshita, F., Klinman, D. M. (2001) Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs. J. Immunol. 166, 2372-2377.
20. Hartmann, G., Battiany, J., Poeck, H., Wagner, M., Kerkmann, M., Lubenow, N., Rothenfusser, S., Endres, S. (2003) Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-α induction in plasmacytoid dendritic cells. Eur. J. Immunol. 33, 1633-1641.
21. Verthelyi, D., Puig, M. (2008) Structure/function of IFNα inducing CpG ODN. In Nucleic Acids in Innate Immunity (K. J.Ishii, S.Akira, eds.), CRC Press, Boca Raton, FL, USA, 113-128.
22. Krieg, A. M. (2006) Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5, 471-484.
23. Marshall, J. D., Fearon, K., Abbate, C., Subramanian, S., Yee, P., Gregorio, J., Coffman, R. L., Van Nest, G. (2003) Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J. Leukoc. Biol. 73, 781-792.
24. Latz, E., Schoenmeyer, A., Visintin, A., Fitzgerald, K. A., Monks, B. G., Knetter, C. F., Lien, E., Nilsen, N. J., Espevik, T., Golenbock, D. T. (2004) TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 5, 190-198.
25. Leifer, C. A., Brooks, J. C., Hoelzer, K., Lopez, J. L., Kennedy, M. N., Mazzoni, A., Segal, D. M. (2006) Cytoplasmic targeting motifs control localization of Toll-like receptor 9. J. Biol. Chem. 281, 35585-35592.
26. Latz, E., Verma, A., Visintin, A., Gong, M., Sirois, C. M., Klein, D. C. G., Monks, B. G., McKnight, C. J., Lamphier, M. S., Duprex, W. P., Espevik, T., Golenbock, D. T. (2007) Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat. Immunol. 8, 772-779.
27. Sasai, M., Linehan, M. M., Iwasaki, A. (2010) Bifurcation of Toll-like receptor 9 signaling by adaptor protein 3. Science 329, 1530-1534.
28. Verthelyi, D., Kenney, R. T., Seder, R. A., Gam, A. A., Friedag, B., Klinman, D. M. (2002) CpG oligodeoxynucleotides as vaccine adjuvants in primates. J. Immunol. 168, 1659-1663.
29. Löeseke, S., Grage-Griebenow, E., Wagner, A., Gehlhar, K., Bufe, A. (2003) Differential expression of IFN-α subtypes in human PBMC: evaluation of novel real-time PCR assays. J. Immunol. Methods 276, 207-222.
30. Giesendorf, B. A. J., Vet, J. A. M., Tyagi, S., Mensink, E. J. M. G., Trijbels, F. J. M., Blom, H. J. (1998) Molecular beacons: a new approach for semiautomated mutation analysis. Clin. Chem. 44, 482-486.
31. Koshkin, A. A., Singh, S. K., Nielsen, P., Rajwanshi, V. K., Kumar, R., Meldgaard, M., Olsen, C. E., Wengel, J. (1998) LNA (locked nucleic acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerization, and unprecedented nucleic acid recognition. Tetrahedron 54, 3607-3630.
32. Zeuner, R. A., Klinman, D. M., Illei, G., Yarboro, C., Ishii, K. J., Gursel, M., Verthelyi, D. (2003) Response of peripheral blood mononuclear cells from lupus patients to stimulation by CpG oligodeoxynucleotides. Rheumatology 42, 563-569.
33. Verthelyi, D., Klinman, D. M. (2003) Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin. Immunol. 109, 64-71.
34. Gardner, M. B., Luciw, P. A. (2008) Macaque models of human infectious disease. ILAR J. 49, 220-255.
35. Verthelyi, D., Gursel, M., Kenney, R. T., Lifson, J. D., Shuying, L., Mican, J., Klinman, D. M. (2003) CpG oligodeoxynucleotides protect normal and SIV infected macaques from Leishmania infection. J. Immunol. 170, 4717-4723.
36. Hartmann, G., Weeratna, R. D., Ballas, Z. K., Payette, P., Blackwell, S., Suparto, I., Rasmussen, W. L., Waldshmidt, M., Sajuthi, D., Purcell, R. H., Davis, H. L., Krieg, A. M. (2000) Delineation of a CpG phosphorothioate oligodeoxinucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 164, 1617-1624.
37. Weber, J. S., Zarour, H., Redman, B., Trefzer, U., O'Day, S., van den Eertwegh, A. J. M., Marshall, E., Wagner, S. (2009) Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer 115, 3944-3954.
38. Saiag, P., Bauhofer, A., Bouscarat, F., Aquilina, C., Ortonne, J. P., Dupin, N., Mougin, C. (2009) Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study. Br. J. Dermatol. 161, 904-909.
39. Ozolins, M., Williams, H., Armstrong, S., Bath-Hextall, F. (2010) The SINS trial: A randomized controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma. Trials 11, 42.
40. Di Domizio, J., Blum, A., Gallagher-Gambarelli, M., Molens, J. P., Chaperot, L., Plumas, J. (2009) TLR7 stimulation in human plasmacytoid dendritic cells leads to the induction of early IFN-inducible genes in the absence of type I IFN. Blood 114, 1794-1802.
41. Yanai, Y., Sanou, O., Kayano, T., Ariyasu, H., Yamamoto, K., Yamauchi, H., Ikegami, H., Kurimoto, M. (2001) Analysis of the antiviral activities of natural IFN-α preparations and their subtype compositions. J. Interferon Cytokine Res. 21, 835-841.
42. Koyama, T., Sakamoto, N., Tanabe, Y., Nakagawa, M., Itsui, Y., Takeda, Y., Kakinuma, S., Sekine, Y., Maekawa, S., Yanai, Y., Kurimoto, M., Watanabe, M. (2006) Divergent activities of interferon-α subtypes against intracellular hepatitis C virus replication. Hepatol. Res. 34, 41-49.
43. Hirankarn, N., Tangwattanachuleeporn, M., Wongpiyabovorn, J., Wongchinsri, J., Avihingsanon, Y. (2008) Genetic association of interferon-α subtypes 1, 2 and 5 in systemic lupus erythematosus. Tissue Antigens 72, 588-592.
44. Schoggins, J. W., Wilson, S. J., Panis, M., Murphy, M. Y., Jones, C. T., Bieniasz, P., Rice, C. M. (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481-485.
45. Coccia, E. M., Severa, M., Giacomini, E., Monneron, D., Remoli, M. E., Julkunen, I., Cella, M., Lande, R., Uze, G. (2004) Viral infection and Toll-like receptor agonists induce a differential expression of type I and λ interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur. J. Immunol. 34, 796-805.
46. Ewald, S. E., Engel, A., Lee, J., Wang, M., Bogyo, M., Barton, G. M. (2011) Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase. J. Exp. Med. 208, 643-651.
47. O'Brien, M., Manches, O., Sabado, R. L., Baranda, S. J., Wang, Y., Rolnitzky, L., Markowitz, M., Margolis, D. M., Bhardwaj, N. (2011) Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-α-producing and partially matured phenotype. J. Clin. Invest. 121, 1088-1101.
48. Guiducci, C., Ott, G., Chan, J. H., Damon, E., Calacsan, C., Matray, T., Lee, K. D., Coffman, R. L., Barrat, F. J. (2006) Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J. Exp. Med. 203, 1999-2008.
49. Honda, K., Yanai, H., Takaoka, A., Taniguchi, T. (2005) Regulation of the type I IFN induction: a current view. Int. Immunol. 17, 1367-1378.
50. Honda, K., Ohba, Y., Yanai, H., Negishi, H., Mizutani, T., Takaoka, A., Taya, C., Taniguchi, T. (2005) Spatiotemporal regulation of MyD88-IRF-7 signaling for robust type-I interferon induction. Nature 434, 1035-1040.
51. Kerkmann, M., Rothenfusser, S., Hornung, V., Towarowski, A., Wagner, M., Sarris, A., Giese, T., Endres, S., Hartmann, G. (2003) Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J. Immunol. 170, 4465-4474.
52. Chockalingam, A., Brooks, J. C., Cameron, J. L., Blum, L. K., Leifer, C. A. (2009) TLR9 traffics through the Golgi complex to localize to endolysosomes and respond to CpG DNA. Immunol. Cell Biol. 87, 209-217.
53. Barton, G. M., Kagan, J. C. (2009) A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat. Rev. Immunol. 9, 535-542.
54. Chockalingam, A., Cameron, J. L., Brooks, J. C., Leifer, C. A. (2011) Negative regulation of signaling by a soluble form of Toll-like receptor 9. Eur. J. Immunol. 41, 2176-2184.
55. Génin, P., Lin, R., Hiscott, J., Civas, A. (2009) Differential regulation of human interferon A gene expression by interferon regulatory factors 3 and 7. Mol. Cell. Biol. 29, 3435-3450.
56. Génin, P., Vaccaro, A., Civas, A. (2009) The role of differential expression of human interferon-A genes in antiviral immunity. Cytokine Growth Factor Rev. 20, 283-295.
57. Szubin, R., Chang, W., Greasby, T., Beckett, L., Baumgarth, N. (2008) Rigid interferon-α subtype responses of human plasmacytoid dendritic cells. J. Interferon Cytokine Res. 28, 749-763.
58. Savitsky, D., Tamura, T., Yanai, H., Taniguchi, T. (2010) Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunol. Immunother. 59, 489-510.
59. Maiwald, T., Schneider, A., Busch, H., Sahle, S., Gretz, N., Weiss, T. S., Kummer, U., Klingmüller, U. (2010) Combining theoretical analysis and experimental data generation reveals IRF9 as a crucial factor for accelerating interferon-α-induced early antiviral signaling. FEBS J. 277, 4741-4754.
60. Easlick, J., Szubin, R., Lantz, S., Baumarth, N., Abel, K. (2010) The early interferon-α subtype response in infant macaques infected orally with SIV. J. Acquir. Immune Defic. Syndr. 55, 14-28.